Evidence map›Paper›PMID 31175329›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.

Tao Wang, Lik Hang Lee, Monika Vyas, Liying Zhang, Karuna Ganesh, Canan Firat, Neil H Segal, Avni Desai, Jaclyn F Hechtman, Peter Ntiamoah and 6 more

Abstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Lynch Syndrome: Its Impact on Urothelial Carcinoma.International journal of molecular sciences · 2021
    Review
  8. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tao WangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lik Hang LeeDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Monika VyasDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Liying ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karuna GaneshDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Canan FiratDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Neil H SegalDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Avni DesaiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Peter NtiamoahDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Martin R WeiserDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnold J MarkowitzDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Efsevia VakianiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David S KlimstraDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Stadlerz@mskcc.org.
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Shiaj@mskcc.org.ORCID http://orcid.org/0000-0002-4351-2511

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Investigating L1CAM-dependent stem cell regeneration in metastasisK08CA230213 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GANESH, KARUNA · 2018 to 2022
$1.3M
NCI NIH HHS K08 CA230213NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Double somatic mismatch-repair-gene mutation/alteration is a recently recognized molecular mechanism that underlies microsatellite instability-high in some colorectal carcinomas. It remains to be determined whether and how microsatellite instability-high tumors with this molecular defect differ from their counterparts caused by other mechanisms, specifically, Lynch syndrome-associated and MLH1-promoter hypermethylated. In this study, we evaluated the clinical and pathological characteristics of a series of 15 double somatic mutation/alteration-associated microsatellite instability-high colorectal carcinomas identified from our genetics service and 68 such cases reported in the literature. We observed that these cases presented at an age similar to MLH1-promoter hypermethylated (n = 20) and microsatellite-stable (n = 39) cases but older than Lynch syndrome-associated cases (n = 20, p < 0.05). While these tumors simulated other microsatellite instability-high tumors in their prevalent right-sided location, they appeared to differ in TNM stages at presentation (73% stage III/IV versus 25% stage III/IV in other microsatellite instability-high tumors, p = 0.04). Histologically, 40% of them had a dominant solid growth pattern. Inter-tumoral heterogeneity was a striking feature, spanning the spectrum from medullary type (with a tumor-infiltrating-lymphocyte/high-power-field count as high as 59) to conventional-type with only few tumor-infiltrating-lymphocytes (1/high-power-filed). As a group, these tumors seemed less likely to show robustly high lymphocytic infiltration than other microsatellite instability-high tumors (only 20% had ≥10 tumor-infiltrating-lymphocytes/high-power-filed, whereas this rate in Lynch syndrome-associated and MLH1-promoter hypermethylated tumors was 60% and 75%, respectively). Three double somatic mutation/alteration-associated tumors were treated with a PD1/PD-L1 checkpoint inhibitor. While all three had an elevated tumor-mutation-burden (>47 mut/megabase), only one had tumor-infiltrating-lymphocytes >10/high-power-field, yet all three exhibited measurable response. In summary, microsatellite instability-high colorectal carcinomas caused by double somatic mismatch-repair-gene mutation/alteration may have varied clinical and pathological characteristics, and some may have relatively low tumor-infiltrating-lymphocytes; response to immune checkpoint inhibitors can be achieved in this group even when the lymphocytic infiltration is not abundant.

Indexed as

DNA Mismatch RepairMicrosatellite InstabilityAdultAgedAntineoplastic Agents, ImmunologicalBiomarkers, TumorColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisFemaleHumansMaleMiddle AgedMutL Protein Homolog 1Treatment OutcomeAntineoplastic Agents, ImmunologicalBiomarkers, TumorMutL Protein Homolog 1

Identifiers

PMID31175329
PMCPMC6849386

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.